[go: up one dir, main page]

RS20060578A - Method for the purification of albumin conjugates - Google Patents

Method for the purification of albumin conjugates

Info

Publication number
RS20060578A
RS20060578A RSP-2006/0578A RSP20060578A RS20060578A RS 20060578 A RS20060578 A RS 20060578A RS P20060578 A RSP20060578 A RS P20060578A RS 20060578 A RS20060578 A RS 20060578A
Authority
RS
Serbia
Prior art keywords
albumin
albumin conjugates
conjugates
purification
solution
Prior art date
Application number
RSP-2006/0578A
Other languages
English (en)
Inventor
Dominique Bridon
Gagnon Nathalie Bousquet
Omar Quraishi
Original Assignee
Conjuchem Biotechnologies Inc.,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35196920&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS20060578(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Conjuchem Biotechnologies Inc., filed Critical Conjuchem Biotechnologies Inc.,
Publication of RS20060578A publication Critical patent/RS20060578A/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/303—Extraction; Separation; Purification by precipitation by salting out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/16—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to the conditioning of the fluid carrier
    • B01D15/166—Fluid composition conditioning, e.g. gradient
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • B01D15/426—Specific type of solvent

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Postupak za odvajanje albuminskih konjugata od nekonjugovanog albumina iz rastvora koji uključuje albuminske konjugate i nekonjugovani albumin hidrofobnom interakcionom hromatografijom (HIC). Rastvor se nanese na hidrofobnu kolonu uravnoteženu vodenim puferom koji poseduje visoki sadržaj soli; primenjujući na kolonu gradijent opadanja koncentracije soli; i sakupljanjem eluiranih albuminskih konjugata.
RSP-2006/0578A 2004-04-23 2005-04-22 Method for the purification of albumin conjugates RS20060578A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56522804P 2004-04-23 2004-04-23
PCT/CA2005/000614 WO2005103087A1 (en) 2004-04-23 2005-04-22 Method for the purification of albumin conjugates

Publications (1)

Publication Number Publication Date
RS20060578A true RS20060578A (en) 2008-11-28

Family

ID=35196920

Family Applications (1)

Application Number Title Priority Date Filing Date
RSP-2006/0578A RS20060578A (en) 2004-04-23 2005-04-22 Method for the purification of albumin conjugates

Country Status (24)

Country Link
US (3) US7307148B2 (sr)
EP (3) EP2100904B1 (sr)
JP (1) JP2007535507A (sr)
CN (1) CN1956998B (sr)
AT (2) ATE473244T1 (sr)
AU (1) AU2005235634B2 (sr)
BR (1) BRPI0510117A (sr)
CA (1) CA2564031A1 (sr)
DE (2) DE602005022239D1 (sr)
DK (2) DK1745078T3 (sr)
EA (1) EA011168B1 (sr)
ES (2) ES2347902T3 (sr)
HR (1) HRP20060362A2 (sr)
IL (1) IL178369A0 (sr)
MA (1) MA28587B1 (sr)
MX (1) MXPA06012260A (sr)
NO (1) NO20065037L (sr)
PL (2) PL1745078T3 (sr)
PT (2) PT1745078E (sr)
RS (1) RS20060578A (sr)
SI (2) SI2100904T1 (sr)
TN (1) TNSN06340A1 (sr)
WO (1) WO2005103087A1 (sr)
ZA (1) ZA200608475B (sr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
DE60000665T3 (de) * 1999-05-17 2009-10-29 ConjuChem Biotechnologies Inc., Montreal Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
WO2002066511A2 (en) * 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
EP1390399B1 (en) * 2001-05-31 2005-05-11 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
PT1745078E (pt) 2004-04-23 2009-09-17 Conjuchem Biotechnologies Inc Método para a purificação de conjugados de albumina
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
WO2007053946A1 (en) 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US7982018B2 (en) * 2006-10-16 2011-07-19 Conjuchem, Llc Modified corticotropin releasing factor peptides and uses thereof
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US20090088378A1 (en) * 2007-01-12 2009-04-02 Omar Quraishi Long lasting inhibitors of viral infection
EP2147016A2 (en) * 2007-05-16 2010-01-27 ConjuChem Biotechnologies Inc. Cysteic acid derivatives of anti-viral peptides
WO2008157824A2 (en) * 2007-06-21 2008-12-24 Conjuchem Biotechnologies Inc. Thrombopoietin peptide conjugates
EP2231191A2 (en) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation of insulinotropic peptide conjugates
EP2247298B1 (en) * 2007-12-31 2016-08-31 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
ES2563553T3 (es) 2008-04-01 2016-03-15 Novo Nordisk A/S Conjugados de insulina-albúmina
CN101987868B (zh) * 2009-07-30 2013-09-04 江苏豪森医药集团有限公司 Glp-1类似物的衍生物或其可药用盐和用途
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
US9744155B2 (en) 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
EP3092010B1 (en) * 2014-01-10 2018-07-11 Synthon Biopharmaceuticals B.V. Method for purifying cys-linked antibody-drug conjugates
JP6830355B2 (ja) * 2014-01-31 2021-02-17 イクセラ，インコーポレイテッド バイオマーカーとしての共有結合した代謝物質
WO2016065052A1 (en) * 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
CN105111306A (zh) * 2015-08-28 2015-12-02 北京工业大学 美洲短吻鳄白蛋白的分离方法
WO2017165607A1 (en) 2016-03-24 2017-09-28 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
CA3084326A1 (en) 2017-09-28 2019-04-04 Jaehyuk Choi Long-acting conjugates of glp-2 derivatives
CN108840922A (zh) * 2018-06-04 2018-11-20 河北常山生化药业股份有限公司 分离白蛋白非结合物、白蛋白结合物和小分子化合物的方法
CN108977423A (zh) * 2018-08-17 2018-12-11 集美大学 一种从猪肺中分离提纯血管紧张素转化酶的方法
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109721653B (zh) * 2019-03-05 2023-02-03 嘉兴学院 一种胰高血糖素样肽-1片段类似物及其应用
CN115397846A (zh) * 2020-03-06 2022-11-25 昆山新蕴达生物科技有限公司 疏水性修饰的白蛋白及其制备方法和用途
WO2021222759A1 (en) * 2020-04-30 2021-11-04 Board Of Regents, The University Of Texas System Albumin drug conjugates and use thereof for the treatment of cancer
US12161777B2 (en) 2020-07-02 2024-12-10 Davol Inc. Flowable hemostatic suspension
US11739166B2 (en) 2020-07-02 2023-08-29 Davol Inc. Reactive polysaccharide-based hemostatic agent
EP4225462A1 (en) * 2020-10-05 2023-08-16 Sartorius BIA Separations d.o.o. Improved removal of rna and contaminants from dna plasmid preparations by hydrophobic interaction chromatography
CN116744984A (zh) 2020-12-28 2023-09-12 达沃有限公司 包含蛋白质和多官能化改性的基于聚乙二醇的交联剂的反应性干粉状止血材料

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4206199A (en) 1977-07-22 1980-06-03 Takeda Chemical Industries, Ltd. Novel glucagon fragment and its derivatives
US4251631A (en) 1978-02-23 1981-02-17 Research Products Rehovot Ltd. Cross-linked enzyme membrane
US4423034A (en) 1980-10-16 1983-12-27 Toyo Jozo Kabushiki Kaisha Process for the preparation of antibodies
US4678671A (en) * 1981-12-15 1987-07-07 Cordis Europa N.V. Conjugates of anticoagulant and protein
US4462941A (en) 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4745100A (en) 1985-05-14 1988-05-17 Eye Research Institute Of Retina Foundation Stimulation of tear secretion
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5614492A (en) 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4859604A (en) 1987-08-27 1989-08-22 Ampor, Inc. Composition for stabilization of diagnostic reagents
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5725804A (en) 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DE69226077T2 (de) 1991-04-05 1998-12-03 Genentech, Inc., South San Francisco, Calif. PLAETTCHENAGGREGATIONSINHIBITOREN MIT HOHER SPEZIFIZITAET ZUM GP IIbIIIa
US5103233A (en) 1991-04-16 1992-04-07 General Electric Co. Radar system with elevation-responsive PRF control, beam multiplex control, and pulse integration control responsive to azimuth angle
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
JPH07102148B2 (ja) * 1992-05-20 1995-11-08 株式会社ミドリ十字 遺伝子操作により得られるヒト血清アルブミンの製造方法、およびそれにより得られるヒト血清アルブミン含有組成物
US5807827A (en) 1992-06-12 1998-09-15 Des-Tyr Dynorphin Partnership Des-Tyr dynorphin analogues
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5614487A (en) 1993-05-28 1997-03-25 Genentech, Inc. Sustained release pharmaceutical composition
US20020018751A1 (en) 1993-10-15 2002-02-14 BRIDON Dominique P. Cellular and serum protein anchors for diagnostic imaging
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
DK145493D0 (da) 1993-12-23 1993-12-23 Dako As Antistof
US5580853A (en) 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
JPH10502333A (ja) 1994-04-07 1998-03-03 プロティーンニックス カンパニー バソアクティブ・インテスティナル・ポリペプチド
EP0788371A1 (en) 1994-08-26 1997-08-13 LEE, Nancy M. Analgesic method with dynorphin analogues truncated at the n-terminus
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
CA2157219C (en) * 1994-08-31 2010-10-05 Munehiro Noda Process for purifying recombinant human serum albumin
US5939390A (en) 1995-03-09 1999-08-17 Novo Nordisk A/S Pharmaceutical composition
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5654276A (en) 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
WO1997025074A2 (en) 1996-01-12 1997-07-17 Redcell Canada, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
DK0915910T3 (da) 1996-06-05 2006-05-22 Roche Diagnostics Gmbh Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
JP2001501593A (ja) 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CA2265454A1 (en) 1996-09-09 1998-03-19 Zealand Pharmaceuticals A/S Peptide prodrugs containing an alpha-hydroxyacid linker
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
EP0941114B1 (en) 1996-11-12 2005-02-23 Novo Nordisk A/S Use of glp-1 peptides
JP4671372B2 (ja) * 1996-11-15 2011-04-13 ジェネンテック， インコーポレイテッド ニューロトロフィンの精製
EP1629849B2 (en) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Pharmaceutical compositions comprising exendins and agonists thereof
US6723530B1 (en) 1997-02-05 2004-04-20 Amylin Pharmaceuticals, Inc. Polynucleotides encoding proexendin, and methods and uses thereof
US5981488A (en) 1997-03-31 1999-11-09 Eli Lillly And Company Glucagon-like peptide-1 analogs
CA2309205A1 (en) 1997-11-07 1999-05-20 Conjuchem, Inc. Novel conjugates of rgd-containing peptides and endogenous carriers
DE69839946D1 (de) 1997-11-07 2008-10-09 Conjuchem Biotechnologies Inc Methoden zum Screening von Affinitätsmarker-Bibliotheken
US6437092B1 (en) 1998-11-06 2002-08-20 Conjuchem, Inc. Conjugates of opioids and endogenous carriers
US6703359B1 (en) 1998-02-13 2004-03-09 Amylin Pharmaceuticals, Inc. Inotropic and diuretic effects of exendin and GLP-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1950224A3 (en) 1998-03-09 2008-12-17 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6107489A (en) 1998-03-17 2000-08-22 Conjuchem, Inc. Extended lifetimes in vivo renin inhibitors
US6998387B1 (en) 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
US20030170250A1 (en) 1998-03-23 2003-09-11 Ezrin Alan M. Local delivery of long lasting therapeutic agents
US6284725B1 (en) 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US6440417B1 (en) 1998-11-06 2002-08-27 Conjuchem, Inc. Antibodies to argatroban derivatives and their use in therapeutic and diagnostic treatments
AU777564B2 (en) 1999-01-14 2004-10-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
DK1143989T3 (da) 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
DE60000665T3 (de) 1999-05-17 2009-10-29 ConjuChem Biotechnologies Inc., Montreal Lang wirkende peptidinhibitoren der virusfusion mit körperzellen bei viralen infektionen
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US20040266673A1 (en) 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6329336B1 (en) 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
EP2100901A1 (en) 1999-05-17 2009-09-16 ConjuChem Biotechnologies Inc. Modified Insulin and conjugates thereof
US6514500B1 (en) 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
WO2000070665A2 (en) 1999-05-17 2000-11-23 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6506724B1 (en) 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE60036367T2 (de) 1999-06-21 2008-05-29 Eli Lilly And Co., Indianapolis Synergitische verwendung von thiazolidinedionen und glucagon-ähnlichem peptid-1 und dessen agonisten für die behandlung von nicht-insulin-abhängigen diabetes
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
DE19932782A1 (de) * 1999-07-14 2001-01-18 Biotest Pharma Gmbh Verfahren zur chromatographischen Fraktionierung von Plasma oder Serum, so erhaltene Präparate und deren Verwendung
DE19936780A1 (de) 1999-08-09 2001-02-15 Basf Ag Neue Antagonisten von Integrinrezeptoren
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
US20020003999A1 (en) * 2000-03-09 2002-01-10 Claus Bonde Discharge and stacker device
CA2405550A1 (en) * 2000-04-12 2001-10-25 Human Genome Sciences, Inc. Albumin fusion proteins
WO2001089554A2 (en) 2000-05-19 2001-11-29 Bionebraska, Inc. Treatment of acute coronary syndrome with glp-1
NZ519752A (en) 2000-10-20 2005-04-29 Amylin Pharmaceuticals Inc Treatment of hibernating myocardium and diabetic cardiomyopathy with a GLP-1 peptide
US7259233B2 (en) 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
CN101696240A (zh) * 2001-02-02 2010-04-21 康久化学生物技术公司 长效生长激素释放因子衍生物
WO2002066511A2 (en) 2001-02-16 2002-08-29 Conjuchem Inc. Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
EP1390399B1 (en) 2001-05-31 2005-05-11 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
SE526227C2 (sv) * 2002-05-15 2005-08-02 North China Pharmaceutical Group Metod för rening av rekombinant humant serumalbumin
US6861236B2 (en) 2002-05-24 2005-03-01 Applied Nanosystems B.V. Export and modification of (poly)peptides in the lantibiotic way
EP1575490A4 (en) 2002-06-04 2007-08-08 Lilly Co Eli MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1)
US6989369B2 (en) * 2003-02-07 2006-01-24 Dyax Corp. Kunitz domain peptides
CN101665538A (zh) * 2003-12-18 2010-03-10 诺沃挪第克公司 与白蛋白样物质相连的新glp-1类似物
PT1745078E (pt) 2004-04-23 2009-09-17 Conjuchem Biotechnologies Inc Método para a purificação de conjugados de albumina

Also Published As

Publication number Publication date
US20050267293A1 (en) 2005-12-01
ES2347902T3 (es) 2010-11-22
EP2100904B1 (en) 2010-07-07
US20120022234A1 (en) 2012-01-26
DE602005014969D1 (de) 2009-07-30
EA200601959A1 (ru) 2007-04-27
ATE473244T1 (de) 2010-07-15
ATE433999T1 (de) 2009-07-15
EP1745078A1 (en) 2007-01-24
CN1956998B (zh) 2012-12-12
NO20065037L (no) 2007-01-11
EA011168B1 (ru) 2009-02-27
US20080146783A1 (en) 2008-06-19
DK2100904T3 (da) 2010-11-08
CN1956998A (zh) 2007-05-02
EP2100904A1 (en) 2009-09-16
PT1745078E (pt) 2009-09-17
JP2007535507A (ja) 2007-12-06
EP1745078B1 (en) 2009-06-17
HRP20060362A2 (en) 2007-03-31
SI2100904T1 (sl) 2010-10-29
US7307148B2 (en) 2007-12-11
SI1745078T1 (sl) 2009-12-31
DE602005022239D1 (de) 2010-08-19
AU2005235634B2 (en) 2011-10-20
WO2005103087A1 (en) 2005-11-03
PL2100904T3 (pl) 2011-05-31
DK1745078T3 (da) 2009-10-26
TNSN06340A1 (en) 2008-02-22
MA28587B1 (fr) 2007-05-02
PL1745078T3 (pl) 2009-12-31
PT2100904E (pt) 2010-09-24
MXPA06012260A (es) 2006-12-15
EP1745078A4 (en) 2007-08-01
BRPI0510117A (pt) 2007-09-25
ES2328591T3 (es) 2009-11-16
IL178369A0 (en) 2007-02-11
EP2230257A1 (en) 2010-09-22
HK1136305A1 (en) 2010-06-25
ZA200608475B (en) 2007-11-28
CA2564031A1 (en) 2005-11-03
AU2005235634A1 (en) 2005-11-03
HK1096102A1 (en) 2007-05-25

Similar Documents

Publication Publication Date Title
RS20060578A (en) Method for the purification of albumin conjugates
JP2005206602A5 (sr)
WO2007109163A3 (en) Wash buffer and method of using
WO2006138553A3 (en) Methods of purifying fc region containing proteins
EP1568710A3 (en) Antibody purification method
DK1156835T3 (da) Fremgangsmåde til radiomærkning af proteiner med Yttrium-90
EP2161573A4 (en) MONOLITH ADSORBENS, AND METHOD AND DEVICE FOR ADSORPING SAMPLES THEREWITH
MX342922B (es) Purificacion de insulina.
WO2003065031A1 (en) Method and apparatus for analyzing amino acid, peptide, protein, saccharide or lipid
NZ599323A (en) Affinity ligands and methods for protein purification
ATE496935T1 (de) Verfahren zur aufreinigung hydrophober proteine
WO2007065918A3 (en) Method for purifying fsh or a fsh mutant
PL1841863T3 (pl) Sposób oczyszczania czynnika VII
DK1064066T3 (da) Adsorptionschromatografi
MY157846A (en) Process for the purification of fc-containing proteins
ATE461199T1 (de) Verfahren zur trennung und reinigung von hydrocodon durch präparative chromatographie
SE0402558D0 (sv) A process for the purification of antibodies
EP1923126A4 (en) METHOD FOR CONCENTRATING OXYGEN ISOTOPES
EP1712905A4 (en) METHOD FOR SEPARATING OPTICAL ISOMERS USING SUPERCRITICAL LIQUID CHROMATOGRAPHY
PT1558354E (pt) Utilização de aminas, aminoácidos ou ésteres de aminoácidos como modificadores da fase móvel em cromatografia
CY1118533T1 (el) Μεθοδος χρωματογραφιας συναφειας αντιδρομβινης iii
DE602004018674D1 (de) Grosstechnisches verfahren zur abtrennung und aufreinigung von fentanyl durch präparative umkehrphasenchromatographie
WO2007139471A3 (en) Method for chromatography
용철순 et al. Simultaneous Determination of Prostaglandin E1 and Prostaglandin E1 Ethyl Ester in Hairless Mouse Skin Homogenate by High-Performance Liquid Chromatography